A study for people looking to transition from Buprenorphine maintenance to VIVITROL

A study for people looking to transition from Buprenorphine maintenance to VIVITROL

Brief description of study

Up to 9 weeks, including Screening (up to 3 weeks), up to 2 weeks for Lead-in Period and residential Treatment Period receiving decreasing doses of Buprenorphine and increasing doses of either active or placebo Naltrexone, 4-5 days for VIVITROL induction and post-VIVITROL monitoring, and a 4-week outpatient follow-up period.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Opioid Addiction, Opioid-Related Disorders
  • Age: Between 18 Years - 60 Years
  • Gender: All
Updated on 12 Jul 2022. Study ID: 825716

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center